IVEVF
Inventiva S.A.
$5.33
0.00%
No data for this timeframe.
Vol
SEC Reports7
Recent Activity
Jun 9, 2026
SEC
Inventiva S.A. filed a 6-K announcing the availability of preparatory documents for its Combined General Meeting on June
6-K — Impact 3/10
Jun 3, 2026
SEC
Inventiva S.A. filed a 6-K announcing the mailing of proxy cards for its Ordinary and Extraordinary General Meeting sche
6-K — Impact 2/10
Jun 3, 2026
SEC
Inventiva S.A. filed a 6-K attaching a Subscription Agreement with funds managed by BlackRock and Claret Capital Partner
6-K — Impact 7/10
Analyst Ratings
8Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 1 mixed, 3 neutral. Avg impact: 4.9/10.
NEUTRAL
6-K
3/10
Inventiva S.A. filed a 6-K announcing the availability of preparatory documents for its Combined Gen
Jun 9, 2026
NEUTRAL
6-K
2/10
Inventiva S.A. filed a 6-K announcing the mailing of proxy cards for its Ordinary and Extraordinary
Jun 3, 2026
BULLISH
6-K
7/10
Inventiva S.A. filed a 6-K attaching a Subscription Agreement with funds managed by BlackRock and Cl
Jun 3, 2026
NEUTRAL
6-K
4/10
Inventiva reported Q1 2026 cash of €75.0M and short-term deposits of €121.5M, down from €99.3M and €
May 26, 2026
BEARISH
6-K
6/10
Inventiva filed its notice of meeting for the Ordinary and Extraordinary General Meeting scheduled J
May 22, 2026
BEARISH
20-F
6/10
Inventiva S.A. reported a significant decline in revenue to $4.5 million in 2025 from $9.2 million i
Apr 8, 2026
MIXED
6-K
6/10
Inventiva reported 2025 full-year results with revenues declining to $4.5 million from $9.2 million
Mar 30, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 94% buy across 16 analysts — 8 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 20.8% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.1B | 2081.4% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 7 | 7 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.